Company · caredx-6be9bc5a
CareDx
4 sourcescompanies-2026-11-14-0.1.0
Cite this record
ConductScience Library. CareDx. Companies, record caredx-6be9bc5a. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/caredx-6be9bc5a
On this page
Company
The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.
- Name
- CareDx
- Trials
- 31
- As lead sponsor
- 17
- As collaborator
- 14
- Recruiting
- 1
- Active, recruiting or not
- 8
- Completed
- 12
- Stopped early, withdrawn or suspended
- 5
- Posted results
- 3
- Trials by phase
- Phase 4 3
- Drugs its trials test
- 3
- Comparisons calculated in its trials
- 0
- First trial registered
- 2013-04-16
- Last update
- 2026-11-10
Source ClinicalTrials.gov
Pipeline3
The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.
| Drug | Highest phase registered | Trials | As lead sponsor | Recruiting | Targets | Mechanism | In Drugs and targets | Source |
|---|---|---|---|---|---|---|---|---|
| BELATACEPT | Phase 4 | 2 | 0 | 0 | CD80, CD86 | T-lymphocyte activation antigen CD80 inhibitor; T-lymphocyte activation antigen CD86 inhibitor | https://conductscience.org/library/drugs/CHEMBL1742990 | Open Targets |
| MYCOPHENOLATE MOFETIL | Not applicable | 1 | 1 | 0 | IMPDH1, IMPDH2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | https://conductscience.org/library/drugs/CHEMBL1456 | Open Targets |
| TACROLIMUS | Not applicable | 1 | 1 | 0 | FKBP1A | FK506-binding protein 1A inhibitor | https://conductscience.org/library/drugs/CHEMBL3989887 | Open Targets |
Trials31
The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.
| Trial | Title | Role | Phase | Status | Type | Participants | Start | Results first posted | Drugs | In Trials | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07927374 | HistoMap AlloSure Renal Biopsies Observational Research Study | Lead sponsor | Not yet recruiting | Observational | 1,250 | 2026-12 | https://conductscience.org/library/trials/NCT07927374 | ClinicalTrials.gov | |||
| NCT07905599 | Molecular Evidence of Rejection Intervention Trial | Lead sponsor | Not applicable | Not yet recruiting | Interventional | 200 | 2027-03 | https://conductscience.org/library/trials/NCT07905599 | ClinicalTrials.gov | ||
| NCT07700563 | Development and Validation of HistoMX, a Gene-Expression Platform for Molecular Interpretation of Kidney Allograft Biopsies | Collaborator | Completed | Observational | 2,410 | 2004-01-01 | https://conductscience.org/library/trials/NCT07700563 | ClinicalTrials.gov | |||
| NCT07607327 | Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD) | Lead sponsor | Enrolling by invitation | Observational | 400 | 2026-09-24 | https://conductscience.org/library/trials/NCT07607327 | ClinicalTrials.gov | |||
| NCT07230886 | Prospective Reduction Of Transplant Complications Through Enhanced Preservation Therapy to Prevent Primary Graft Dysfunction | Collaborator | Not applicable | Recruiting | Interventional | 50 | 2026-04-17 | https://conductscience.org/library/trials/NCT07230886 | ClinicalTrials.gov | ||
| NCT05747053 | Personalization of Immunosuppressive Treatment for Organ Transplant Recipients | Collaborator | Terminated | Observational | 105 | 2020-10-01 | https://conductscience.org/library/trials/NCT05747053 | ClinicalTrials.gov | |||
| NCT05459181 | HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC) | Lead sponsor | Not applicable | Unknown status | Interventional | 930 | 2025-12 | https://conductscience.org/library/trials/NCT05459181 | ClinicalTrials.gov | ||
| NCT05423496 | KidneyCare Immuno-optimization in Renal Allografts (KIRA) | Lead sponsor | Not applicable | Withdrawn | Interventional | 0 | 2022-08 | MYCOPHENOLATE MOFETIL, TACROLIMUS | https://conductscience.org/library/trials/NCT05423496 | ClinicalTrials.gov | |
| NCT05060991 | Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients | Collaborator | Phase 4 | Active, not recruiting | Interventional | 14 | 2021-09-24 | https://conductscience.org/library/trials/NCT05060991 | ClinicalTrials.gov | ||
| NCT05050955 | AlloSure Lung Assessment and Metagenomics Outcomes Study | Lead sponsor | Active, not recruiting | Observational | 550 | 2021-10-29 | https://conductscience.org/library/trials/NCT05050955 | ClinicalTrials.gov |
1 to 10 of 31
See all 31 trialsConditions49
The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.
| Condition | Trials |
|---|---|
| Kidney Transplant Rejection | 7 |
| Immunosuppression | 4 |
| Allograft | 2 |
| Antibody Mediated Rejection | 2 |
| COVID-19 | 2 |
| Cardiac Transplant Failure | 2 |
| Cardiac Transplant Rejection | 2 |
| Heart Diseases | 2 |
| Heart Transplant Rejection | 2 |
| Kidney Transplant | 2 |
1 to 10 of 49Source ClinicalTrials.gov
See all 49 conditionsPartners26
The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.
| Organization | Class | Trials shared | In Companies | Source |
|---|---|---|---|---|
| Duke University | Other | 2 | ClinicalTrials.gov | |
| Massachusetts General Hospital | Other | 2 | ClinicalTrials.gov | |
| Arkana Labs | Unknown | 1 | ClinicalTrials.gov | |
| Cedars-Sinai Medical Center | Other | 1 | ClinicalTrials.gov | |
| George Washington University | Other | 1 | ClinicalTrials.gov | |
| London Health Sciences Centre | Other | 1 | ClinicalTrials.gov | |
| Montefiore Medical Center | Other | 1 | ClinicalTrials.gov | |
| Montreal Heart Institute | Other | 1 | ClinicalTrials.gov | |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NIH | 1 | ClinicalTrials.gov | |
| OrganX | Unknown | 1 | ClinicalTrials.gov |
1 to 10 of 26
See all 26 partnersData dates
The date of each source this release read.
Sources 4
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL
- ClinicalTrials.govNo license stated
- Open TargetsCC0 1.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this company from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/companies/v1/caredx-6be9bc5a
GET https://conductscience.org/api/companies/v1/caredx-6be9bc5a/trials?page=2